B2i Digital, Inc. has announced that Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has been selected as a B2i Digital Featured Company, highlighting the clinical-stage biopharmaceutical company's progress with its INTASYL® siRNA gene-silencing technology. Phio's lead candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma.
In its Phase 1b trial, 22 patients completed treatment across five dose-escalation cohorts, including the fifth and final cohort at the maximum dose concentration. The company reported no dose-limiting toxicities or serious adverse events. At the highest dose cohort, 6 of 7 patients responded, achieving an 85% pathological response. Across all dosing cohorts in cSCC, Phio reported a pathological response rate of approximately 65%, with no disease progression among all treated patients.
Phio has indicated that an FDA submission seeking guidance on next-stage clinical development is targeted for the second quarter of 2026. The company is also advancing Chemistry, Manufacturing Controls and Toxicology fulfillment to satisfy future clinical registration trial initiation. As of its most recent update, Phio reported approximately $21.3 million in cash and cash equivalents, projected to sustain operations into the first half of 2027, supported by 2025 warrant inducement financings totaling approximately $12 million in net proceeds.
In February 2026, Phio strengthened its leadership team ahead of upcoming regulatory engagement and clinical milestones, promoting Lisa Carson to Chief Financial Officer and Jennifer Phillips, Pharm.D., to Senior Vice President, Regulatory and Corporate Affairs, and appointing Kimberly Man as Vice President of Program Development and Strategic Planning to support execution across PH-762 and PH-894. In a February 10, 2026 research report, H.C. Wainwright & Co. reiterated its Buy rating and $14 price target on PHIO following the safety-efficacy update (Source: H.C. Wainwright & Co. Research Report, February 10, 2026).
“We are pleased to support Phio Pharmaceuticals as it advances a differentiated intratumoral immunotherapy platform in large skin cancer markets,” said David Shapiro, Chief Executive Officer of B2i Digital. “The company has reported encouraging response data with a favorable safety profile, strengthened its leadership team, and is funded through key regulatory milestones.” A dedicated Featured Company profile will be available at https://b2idigital.com/featured-companies.
“B2i Digital brings a focused approach to investor outreach,” said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. “With favorable patient safety and pathology data, FDA engagement planned for 2026, and runway extending into 2027, we believe we are well positioned for the next stage of development.” For additional information, visit www.phiopharma.com.
